NasdaqGM - Delayed Quote • USD
Corvus Pharmaceuticals, Inc. (CRVS)
At close: April 24 at 4:00 PM EDT
Earnings Estimate
CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
---|---|---|---|---|
No. of Analysts | 1 | 1 | 1 | 1 |
Avg. Estimate | -0.12 | -0.12 | -0.55 | -0.77 |
Low Estimate | -0.12 | -0.12 | -0.55 | -0.77 |
High Estimate | -0.12 | -0.12 | -0.55 | -0.77 |
Year Ago EPS | -0.17 | -0.14 | -0.56 | -0.55 |
Revenue Estimate
CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
---|---|---|---|---|
No. of Analysts | 2 | 2 | 3 | 1 |
Avg. Estimate | -- | -- | -- | 16.9M |
Low Estimate | -- | -- | -- | 16.9M |
High Estimate | -- | -- | -- | 16.9M |
Year Ago Sales | -- | -- | -- | -- |
Sales Growth (year/est) | -- | -- | -- | -- |
Earnings History
CURRENCY IN USD | 3/31/2023 | 6/30/2023 | 9/30/2023 | 12/31/2023 |
---|---|---|---|---|
EPS Est. | -0.16 | -0.14 | -0.12 | -0.12 |
EPS Actual | -0.17 | -0.14 | -0.12 | -0.14 |
Difference | -0.01 | 0 | 0 | -0.02 |
Surprise % | -6.30% | 0.00% | 0.00% | -16.70% |
EPS Trend
CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
---|---|---|---|---|
Current Estimate | -0.12 | -0.12 | -0.55 | -0.77 |
7 Days Ago | -0.12 | -0.12 | -0.55 | -0.77 |
30 Days Ago | -0.11 | -0.11 | -0.48 | -0.61 |
60 Days Ago | -0.11 | -0.12 | -0.49 | -0.62 |
90 Days Ago | -0.11 | -0.12 | -0.49 | -0.62 |
EPS Revisions
CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
---|---|---|---|---|
Up Last 7 Days | -- | -- | -- | -- |
Up Last 30 Days | -- | -- | -- | -- |
Down Last 7 Days | -- | -- | -- | -- |
Down Last 30 Days | -- | -- | -- | -- |
Growth Estimates
CURRENCY IN USD | CRVS | Industry | Sector | S&P 500 |
---|---|---|---|---|
Current Qtr. | 29.40% | -- | -- | 1.50% |
Next Qtr. | 14.30% | -- | -- | 11.40% |
Current Year | 1.80% | -- | -- | 5.20% |
Next Year | -40.00% | -- | -- | 13.40% |
Next 5 Years (per annum) | -- | -- | -- | 11.09% |
Past 5 Years (per annum) | -- | -- | -- | -- |
Research Analysis
Upgrades & Downgrades
Reiterates | Cantor Fitzgerald: Overweight | 4/1/2024 |
Maintains | Mizuho: Neutral to Neutral | 3/27/2024 |
Maintains | Oppenheimer: Outperform to Outperform | 3/20/2024 |
Reiterates | Cantor Fitzgerald: Overweight to Overweight | 9/7/2023 |
Reiterates | Mizuho: Neutral to Neutral | 6/16/2023 |
Maintains | Ladenburg Thalmann: Buy to Buy | 5/30/2023 |
Related Tickers
LPTX Leap Therapeutics, Inc.
3.2900
+2.81%
CLSD Clearside Biomedical, Inc.
1.3400
-2.19%
AFMD Affimed N.V.
4.8800
-8.79%
PDSB PDS Biotechnology Corporation
3.2500
+1.56%
CTMX CytomX Therapeutics, Inc.
1.6300
-2.98%
EFTR eFFECTOR Therapeutics, Inc.
1.8500
-4.64%
CDTX Cidara Therapeutics, Inc.
12.29
+19.90%
CLRB Cellectar Biosciences, Inc.
3.0600
-1.61%
GLYC GlycoMimetics, Inc.
1.8550
+1.09%
EPIX ESSA Pharma Inc.
6.25
-2.34%